Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 14Brain Neoplasms 10Carcinoma, Hepatocellular 9Neoplasm Metastasis 7Neoplasms 6Pancreatic Neoplasms 5Lung Neoplasms 5Colorectal Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Prostatic Neoplasms 3Melanoma 3Carcinoma, Renal Cell 3Breast Neoplasms 3Glioblastoma 2Adenocarcinoma of Lung 2Triple Negative Breast Neoplasms 1Sarcoma 1Recurrence 1Radiotherapy 1Prostate Cancer Metastatic 1Ovarian Neoplasms 1Neoplasm, Residual 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Liver Neoplasms 1Liver Diseases 1Kidney Neoplasms 1Glioma 1Carcinoma, Transitional Cell 1Carcinoma, Merkel Cell 1

Interventions

nirogacestat 1navoximod 1ixabepilone 1atezolizumab 1Topotecan 1Radiosurgery 1Pemetrexed 1Lapatinib 1Hydroxyurea 1Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Advanced Solid Tumors × Radiosurgery × Clear all
NCT05469490 2022-09-30

Safety of Navoximod and NLG802 With Stereotactic Body Radiotherapy (SBRT) Treatment of Advanced Solid Tumors

University of Pittsburgh

Phase 1 Withdrawn
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡